Regeneron’s COVID-19 Antibody Drug Cocktail Completely Blocks Coronavirus Infection in Animal Test
By HospiMedica International staff writers Posted on 05 Aug 2020 |
Illustration
Regeneron Pharmaceuticals, Inc.’s (Tarrytown, NY, USA) COVID-19 antibody drug combination has prevented as well as treated the disease in rhesus macaques and hamsters, raising hopes of the cocktail treatment working for humans as well.
In animal studies of the antibody treatment on a total of 36 rhesus macaques and 50 hamsters, the company found that the results matched or exceeded the effects recently observed in animal studies of vaccine candidates. In one study, the cocktail of two monoclonal antibodies was able to “almost completely block establishment of virus infection,” according to the company. In a second study involving animals infected with a much higher level of the virus, the company found that the cocktail treatment managed to minimize infection and the prophylactic effect was significantly reduced when the dose was lowered.
Regeneron also found that in infected animals treated with the antibodies, the virus was cleared faster than those administered a placebo. Additionally, the company did not find any signs of a higher viral load or worsening of pathology after treatment in the animals, indicating that the antibody drug combination was unlikely to worsen symptoms in humans as well. Thus, the data suggests that Regeneron’s antibody cocktail therapy could offer clinical benefits in prevention as well as treatment of COVID-19. The company has already initiated late-stage clinical trials in humans to assess the antibody treatment’s ability to prevent and treat COVID-19, and has entered into a contract with the US government as part of its Operation Warp Speed program to provide the US with the treatment if the trials succeed.
Related Links:
Regeneron Pharmaceuticals, Inc.
In animal studies of the antibody treatment on a total of 36 rhesus macaques and 50 hamsters, the company found that the results matched or exceeded the effects recently observed in animal studies of vaccine candidates. In one study, the cocktail of two monoclonal antibodies was able to “almost completely block establishment of virus infection,” according to the company. In a second study involving animals infected with a much higher level of the virus, the company found that the cocktail treatment managed to minimize infection and the prophylactic effect was significantly reduced when the dose was lowered.
Regeneron also found that in infected animals treated with the antibodies, the virus was cleared faster than those administered a placebo. Additionally, the company did not find any signs of a higher viral load or worsening of pathology after treatment in the animals, indicating that the antibody drug combination was unlikely to worsen symptoms in humans as well. Thus, the data suggests that Regeneron’s antibody cocktail therapy could offer clinical benefits in prevention as well as treatment of COVID-19. The company has already initiated late-stage clinical trials in humans to assess the antibody treatment’s ability to prevent and treat COVID-19, and has entered into a contract with the US government as part of its Operation Warp Speed program to provide the US with the treatment if the trials succeed.
Related Links:
Regeneron Pharmaceuticals, Inc.
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans